Image Source: Zacks Investment ... shares of Novo Nordisk’s archrival in the obesity market space, Eli Lilly LLY, gained as its marketed drug, Zepbound (tirzepatide), continues to maintain ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback